An Evaluation of Applicability of Salivary Uric Acid Measurement in Preeclampsia and Normal Pregnancy and Its Correlation with Serum Uric Acid
- 17 Downloads
Hypertensive disorders complicate 5–10% of all pregnancies and contribute greatly to maternal morbidity and mortality. There are various biomarkers for detection of preeclampsia. Several studies have reported that positive correlation exists between serum uric acid (UA) levels and adverse maternal and fetal outcome. Significant advances have been made toward validation of salivary biomarkers. We conducted this study to determine levels of salivary UA and its correlation with serum UA normal pregnancy and preeclampsia.
Present cross-sectional study was conducted in tertiary care teaching hospital in North India. One hundred and fifty participants were divided into control group (50 healthy non-pregnant females), study group I (50 normotensive pregnant females), study group II (50 pregnant females with preeclampsia), and both salivary and serum UA was estimated at the same time.
Saliva UA of study group II (4.86 ± 2.37 mg/dl) was significantly higher (p < 0.001) than that of control group (2.09 ± 1.33 mg/dl) and study group I (3.32 ± 1.77 mg/dl). Serum UA of study group II (6.63 + 2.78 mg/dl) was significantly higher (p < 0.001) than that of control group (2.94 + 1.94 mg/dl) and also study group I (5.18 + 2.31 mg/dl) (p = 0.0006).
UA is present in the saliva of women with preeclampsia and has linear correlation with serum UA. Therefore, salivary UA can be used in place of invasive serum UA to monitor women with preeclampsia. Saliva collection is easy, noninvasive and cost-effective. Salivary UA testing may be useful for monitoring preeclampsia at home-based and hospital setting.
KeywordsSaliva Uric acid Preeclampsia
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008 (5).
Informed consent was obtained from all patients for being included in the study.
- 11.Johnson RJ, Kanbay M, Kang D-H, et al. Uric acid: a clinically useful marker to distinguish preeclampsia from gestational hypertension. Hypertension. 2011;58(4):548–9. https://doi.org/10.1161/hypertensionaha.111.178921.CrossRefGoogle Scholar
- 14.Cunningham FG (2014). Chapter 40: hypertensive disorders. In: Leveno KJ, Bloom SL, Spong CY, Dashe JS, Hoffman BL, Casey BM, Sheffield JS, editors. Williams obstetrics, 24th ed. New York: McGraw-Hill Education. ISBN 9780071798938. OCLC 871619675.Google Scholar
- 16.Hadi BA, Al-jubouri RH. Salivary and plasma analysis of oxidative stress biomarkers in end stage renal failure patients. J Bagh Coll Dent. 2011;23(2):46–50.Google Scholar
- 17.Blicharz TM, Rissin DM, Bowden M, et al. Use of colorimetric test strips for monitoring the effect of hemodialysis on salivary nitrite and uric acid in patients with end-stage renal disease: a proof of principle. Clin Chem. 2008;54(9):1473–80. https://doi.org/10.1373/clinchem.2008.105320.CrossRefGoogle Scholar
- 20.Tejal P, Astha D. Relationship of serum uric acid level to maternal and perinatal outcome in patients with hypertensive disorders of pregnancy. Gujarat Med J. 2014;69(2):45–7.Google Scholar